SCA
SYRE icon

Snowden Capital Advisors’s Spyre Therapeutics SYRE Stock Holding History

Snowden Capital Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,299
Closed -$407K – 684
2020
Q3 		$407K Buy
2,299
+236
+11% +$43.7K 0.03% 425
2020
Q2 		$477K Hold
2,063
– – 0.04% 386
2020
Q1 		$240K Buy
2,063
+12
+0.6% +$2.04K 0.03% 469
2019
Q4 		$392K Buy
+2,051
New +$403K 0.03% 436

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Snowden Capital Advisors's SYRE Position: Q4 2020 in Review

Snowden Capital Advisors sold out of Spyre Therapeutics (SYRE) in Q4 2020, closing a stake of 2,299 shares — an estimated $407K sold.

Snowden Capital Advisors first reported a position in SYRE in Q4 2019 and held it in 4 quarters. The position peaked at $477K in Q2 2020. 92 funds tracked by Wall St. Rank hold SYRE as of Q4 2020.

  • Snowden Capital Advisors reported no remaining Spyre Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Snowden Capital Advisors sold 2,299 Spyre Therapeutics shares in Q4 2020, an estimated $407K.
  • Snowden Capital Advisors first reported a position in Spyre Therapeutics in Q4 2019 and held it in 4 quarters.
  • Snowden Capital Advisors's Spyre Therapeutics position peaked at $477K in Q2 2020.
  • 92 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2020.

Based on Snowden Capital Advisors's 13F filing for Q4 2020, filed 8 Jan 2024.